TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00377000
Drug: clindamycin 1% / benzoyl peroxide 5% gel pump
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00377000
Drug: clindamycin 1% / benzoyl peroxide 5% tube
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02495012
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried powder without snake venom will be dissovled in saline
Study: NCT00875368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT02958878
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03779360
Drug: Erythromycin 4% topical gel formulation:
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
Study: NCT03779360
Drug: Clindamycin 1% lotion formulation:
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
Study: NCT03779360
Drug: Prednisolone tablet (0.5mg/kg; parallel comparison):
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
Study: NCT02139306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo TID
Study: NCT00029185
Drug: Dehydrex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02140489
Drug: amosartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02140489
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02140489
Drug: amosartan and rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00400530
Drug: Comparator: Alendronate-Teva / Duration of Treatment: 1 Month
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01302379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Study: NCT02392130
Drug: LEO 130852A gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01735058
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
Study: NCT01563432
Drug: Feburic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg\*1 tablet
Study: NCT01563432
Drug: TMX-67
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg\*2 tablets
Study: NCT03792971
Drug: GC4419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
Study: NCT00990561
Drug: Ultravate ointment twice daily + LacHydrin lotion twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical corticosteroid
Study: NCT03971071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once every 4 weeks. Subcutaneous injection.
Study: NCT00990561
Drug: Ultravate ointment once daily + LacHydrin lotion twice daily
Normalized name: halobetasol Topical Lotion [Ultravate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid
Study: NCT00408876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00657878
Drug: stealth liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
Study: NCT04147715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT03221907
Drug: GLA5PR GLARS-NF1 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet manufactured to mimic GLA5PR GLARS-NF1
Study: NCT01344395
Drug: ropivacaine and ketorolac
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
Study: NCT01344395
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
Study: NCT03819101
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg
Study: NCT02445391
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04492722
Drug: AZD5718
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.
Study: NCT01176344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert placebo capsules once monthly for 2 years.
Study: NCT05419908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT04492722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once daily oral dose of placebo matched to AZD5718, and will continue until Week 20.
Study: NCT01360632
Drug: Placebo + ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + FDA Approved Antidepressant (ADT)
Study: NCT02867020
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
Study: NCT04021563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single and multiple doses of placebo orally
Study: NCT00141596
Drug: Cardura XL 4 mg bd
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00141596
Drug: Amiloride 5 mg bd
Normalized name: amiloride 5 MG
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01352559
Drug: responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressants administration for 6 weeks under therapeutic dose
Study: NCT01352559
Drug: non-responders
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants administration for 6 weeks under therapeutic dose
Study: NCT04181996
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patents will be randomized to receive either placebo or colchicine
Study: NCT00864942
Drug: BLR-NHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
Study: NCT01098240
Drug: CP-601,927
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
Study: NCT04230265
Drug: Cyclophosphamide (Non-IMP)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion over 3 days
Study: NCT04230265
Drug: TM123 (IMP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion for 20 days
Study: NCT03501550
Drug: CDI-31244
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational drug
Study: NCT03501550
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: sofosbuvir and velpatasvir fixed dose combination
Study: NCT02653092
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02542384
Drug: CR845 IV 1 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Study: NCT00538564
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken orally 3 times a week for 2 months
Study: NCT01956279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
Study: NCT01416376
Drug: SRT2379
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
Study: NCT01416376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
Study: NCT00263276
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks.
Study: NCT04237012
Drug: Dextenza 0.4Mg Intracanalicular Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
Study: NCT02768740
Drug: Hydrocortisone hemisuccinate
Normalized name: Hydrocortisone Hemisuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Study: NCT01709578
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT01709578
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dispensed according to the local practice.
Study: NCT00936884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments).
Study: NCT04333771
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Study: NCT04333771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Study: NCT03096613
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
Study: NCT02797964
Drug: SRA737
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
Study: NCT01859390
Drug: AquADEKs-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
Study: NCT02209779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01361399
Drug: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
Study: NCT01361399
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral application of Aspirin (as lozenge)
Study: NCT01361399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral application of Placebo (as lozenge)
Study: NCT02269215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03105115
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
Study: NCT01865084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02469376
Drug: [18F]-GP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
Study: NCT03052764
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) injection into the bladder.
Study: NCT00004797
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03861611
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
Study: NCT03861611
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
Study: NCT03861611
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
Study: NCT01653483
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel Dry-Powder Inhaler
Study: NCT01653483
Drug: GSK573719matched-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel Dry-Powder Inhaler
Study: NCT01017029
Drug: Mycophenolate mofetil + Everolimus
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01394718
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
Study: NCT04156191
Drug: ARQ-151 cream 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
Study: NCT04156191
Drug: ARQ-151 cream 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
Study: NCT00704912
Drug: Loestrin 1/20
Normalized name: Loestrin 1/20 21 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be started on a low dose containing OCP for a continuous 4 month period.
Study: NCT00096954
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
Study: NCT04505514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding
Study: NCT01671384
Drug: Valproate, Levocarnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
Study: NCT01671384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
Study: NCT01702350
Drug: GSK2251052
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of an an antibacterial
Study: NCT02323659
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 20mg per dose, administered orally, once every week
Study: NCT03197584
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03197584
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03197584
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT03197584
Drug: omega-3 acid ethyl esters
Normalized name: omega-3 acid ethyl esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 acid ethyl esters
Study: NCT01456052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally.
Study: NCT01779947
Drug: Estradiol Vaginal Tablets 10 mcg
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01779947
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03791827
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
Study: NCT03791827
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
Study: NCT03791827
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The recommended dose of azathioprine is 1.5 to 2mg/kg/d
Study: NCT00964132
Drug: NRX194204
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once Daily, Oral
Study: NCT00443612
Drug: Irbesartan/Hydrochlorothiazide
Normalized name: irbesartan/hydrochlorothiazide 300 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
Study: NCT00381251
Drug: Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01037322
Drug: placebo in drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: olive oil containing no drug given in drops twice daily
Study: NCT01442038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Study: NCT00543491
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02746068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00190866
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no